MS Device Selected in Groundbreaking Research in Disease Treatment and Prevention

A mass spectrometer from Thermo Fisher Scientific, Inc. has been chosen by the Institut de Recherches Cliniques de Montreal (ICRM) for use in their proteomics research approach that could impact the current understanding of the human proteome.

A mass spectrometer from Thermo Fisher Scientific, Inc. has been chosen by the Institut de Recherches Cliniques de Montreal (ICRM) for use in their proteomics research approach that could impact the current understanding of the human proteome.

Dr. Benoit Coulombe, his research team at ICRM, and collaborators in various universities and research centers are conducting the research project, called the Human Proteotheque Initiative (HuPI). The overall goal of the project is to define the maps of protein interactions that regulate cell growth, differentiation, and disease progression. Central to the project is its experimental platform, including the LTQ Orbitrap linear ion trap mass spectrometer, which generates maps of protein interaction networks.

This information potentially can lead to future groundbreaking discoveries of new molecular tools for the prevention and treatment of disease.

"What is most important is to develop a highly reliable and efficient discovery pipeline that generates interaction maps that are both as complete and as accurate as possible. The specificity of our procedure to identify functionally relevant interaction partners is spectacular," said Dr. Coulombe.